Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1953 1
1968 1
1970 2
1972 1
1973 1
1975 8
1976 4
1977 8
1978 5
1979 11
1980 6
1981 9
1982 7
1983 5
1984 7
1985 9
1986 13
1987 14
1988 6
1989 4
1990 14
1991 8
1992 7
1993 4
1994 5
1995 10
1996 14
1997 7
1998 16
1999 13
2000 18
2001 24
2002 16
2003 23
2004 39
2005 36
2006 42
2007 37
2008 52
2009 64
2010 71
2011 99
2012 101
2013 95
2014 137
2015 143
2016 125
2017 161
2018 175
2019 180
2020 209
2021 217
2022 233
2023 203
2024 110

Text availability

Article attribute

Article type

Publication date

Search Results

2,475 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Autosomal dominant medullary cystic kidney disease with or without hyperuricemia"
Page 1
Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Yanai H, et al. Int J Mol Sci. 2021 Aug 26;22(17):9221. doi: 10.3390/ijms22179221. Int J Mol Sci. 2021. PMID: 34502127 Free PMC article. Review.
Further, the hyperuricemia observed in patients with renal diseases was considered to be caused by UA underexcretion due to renal failure, and was not considered as an aggressive treatment target. The evidences obtained by basic science suggests a pathogenic …
Further, the hyperuricemia observed in patients with renal diseases was considered to be caused by UA underexcretion du …
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP. Borghi C, et al. Eur J Intern Med. 2020 Oct;80:1-11. doi: 10.1016/j.ejim.2020.07.006. Epub 2020 Jul 29. Eur J Intern Med. 2020. PMID: 32739239 Review.
During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hype …
During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usua …
Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report.
Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, Deltas C, Hosking A, Kmoch S, Rampoldi L, Wiesener M, Wolf MT, Devuyst O; Kidney Disease: Improving Global Outcomes. Eckardt KU, et al. Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4. Kidney Int. 2015. PMID: 25738250 Free article.
Rare autosomal dominant tubulointerstitial kidney disease is caused by mutations in the genes encoding uromodulin (UMOD), hepatocyte nuclear factor-1beta (HNF1B), renin (REN), and mucin-1 (MUC1). Multiple names have been proposed for these disorders, i …
Rare autosomal dominant tubulointerstitial kidney disease is caused by mutations in the genes encoding uromoduli …
Asymptomatic hyperuricaemia: a silent activator of the innate immune system.
Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Joosten LAB, et al. Nat Rev Rheumatol. 2020 Feb;16(2):75-86. doi: 10.1038/s41584-019-0334-3. Epub 2019 Dec 10. Nat Rev Rheumatol. 2020. PMID: 31822862 Free PMC article. Review.
Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence of gout or kidney stones. Yet, increasing evidence suggests that asymptomatic hyperuricaemia can predict the development …
Historically, asymptomatic hyperuricaemia was considered a benign laboratory finding with little clinical importance in the absence o …
Update in uric acid, hypertension, and cardiovascular diseases.
Kuwabara M, Kodama T, Ae R, Kanbay M, Andres-Hernando A, Borghi C, Hisatome I, Lanaspa MA. Kuwabara M, et al. Hypertens Res. 2023 Jul;46(7):1714-1726. doi: 10.1038/s41440-023-01273-3. Epub 2023 Apr 18. Hypertens Res. 2023. PMID: 37072573 Review.
These observation or intervention studies have led to affirm that there is a causal relationship between uric acid and hypertension. While the clinical association between uric acid and high blood pressure is notable, no clear conclusion has yet been reached as to whether …
These observation or intervention studies have led to affirm that there is a causal relationship between uric acid and hypertension. …
An update on the genetics of hyperuricaemia and gout.
Major TJ, Dalbeth N, Stahl EA, Merriman TR. Major TJ, et al. Nat Rev Rheumatol. 2018 Jun;14(6):341-353. doi: 10.1038/s41584-018-0004-x. Nat Rev Rheumatol. 2018. PMID: 29740155 Review.
Genome-wide association studies (GWAS) have confirmed the importance of urate excretion in the control of serum urate levels and the risk of gout and have identified the kidneys, the gut and the liver as sites of urate regulation. The genetic contribution to the progression from …
Genome-wide association studies (GWAS) have confirmed the importance of urate excretion in the control of serum urate levels and the risk of …
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.
Bardin T, Richette P. Bardin T, et al. BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9. BMC Med. 2017. PMID: 28669352 Free PMC article. Review.
Gout, the most prevalent inflammatory arthritis worldwide, is associated with cardiovascular and renal diseases, and is an independent predictor of premature death. The frequencies of obesity, chronic kidney disease (CKD), hypertension, type 2 diabetes …
Gout, the most prevalent inflammatory arthritis worldwide, is associated with cardiovascular and renal diseases, and is an independen …
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
Crawley WT, Jungels CG, Stenmark KR, Fini MA. Crawley WT, et al. Redox Biol. 2022 May;51:102271. doi: 10.1016/j.redox.2022.102271. Epub 2022 Feb 17. Redox Biol. 2022. PMID: 35228125 Free PMC article. Review.
Along with these observations, recent inconclusive data from human studies evaluating the treatment of hyperuricemia with xanthine oxidoreductase (XOR) inhibitors have added to the debate about the causal role of UA in human disease processes. ...We will addr …
Along with these observations, recent inconclusive data from human studies evaluating the treatment of hyperuricemia with xant …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Ferreira JP, Salsali A, Kaempfer C, Brueckmann M, Pocock SJ, Januzzi JL, Packer M. Doehner W, et al. Eur Heart J. 2022 Sep 21;43(36):3435-3446. doi: 10.1093/eurheartj/ehac320. Eur Heart J. 2022. PMID: 35788657 Free PMC article. Clinical Trial.
As a hypothesis-generating finding, an interaction between SUA and treatment effect suggested a benefit of empagliflozin on mortality (cardiovascular and all-cause mortality) in patients in elevated SUA (P for interaction = 0.005 and = 0.011, respectively). CONCLUSION: Hyperur …
As a hypothesis-generating finding, an interaction between SUA and treatment effect suggested a benefit of empagliflozin on mortality (cardi …
Febuxostat.
Hair PI, McCormack PL, Keating GM. Hair PI, et al. Drugs. 2008;68(13):1865-74. doi: 10.2165/00003495-200868130-00006. Drugs. 2008. PMID: 18729537 Review.
*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout. *In a randomized, double-blind, dose-ranging study in patients with gout and hyperuricaemia, signi …
*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperur …
2,475 results